Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Arun J. Sanyal(Virginia Commonwealth University), James Tonascia(Johns Hopkins University), David E. Kleiner(National Institutes of Health), Mariana Lazo(Drexel University), Rohit Loomba(University of California San Diego), Mark L. Van Natta(Johns Hopkins University), Cynthia Behling(Johns Hopkins University), Jeanne M. Clark(Johns Hopkins University), Bilal Hameed(University of California, San Francisco), Brent A. Neuschwander‐Tetri(Saint Louis University), Laura Wilson(Johns Hopkins University), Naga Chalasani(Indiana University – Purdue University Indianapolis), Katherine P. Yates(Johns Hopkins University), Kris V. Kowdley(Liver Institute Northwest), Srinivasan Dasarathy(Cleveland Clinic), Anna‐Mae Diehl(Johns Hopkins University), Patricia Belt(Johns Hopkins University)
Cited by 1,060
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k